Geneos Therapeutics, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Geneos Therapeutics, Inc. - overview
Established
2016
Location
-, PA, US
Primary Industry
Biotechnology
About
Founded in 2017 and based in Pennsylvania, US, Geneos Therapeutics, Inc. operates as a developer of immunotherapies targeting neoantigens from tumors which serves as a treatment for cancer. The company was founded by its President and Chief Executive Officer Niranjan Y. Sardesai.
In March 2023, Geneos Therapeutics, Inc. raised USD 4. 9 million in series A funding from 3B Future Health Fund. Geneos has a neoantigen-targeting platform called GT-EPIC™ that is based on a DNA medicines technology licensed from Inovio Pharmaceuticals, Inc.
The GT-EPIC™ platform allows Geneos to identify relevant neoantigen targets from individual patient tumors to develop novel treatments for cancer. As of 2021, the company is pursuing three clinical pipeline programs: GT-10, GT-20, and GT-30. GT-10 is a clinical trial for Geneos’s neoantigen-targeted personalized vaccine, GNOS-PV02 for the treatment of a patient with anaplastic astrocytoma. GT-20 is a clinical trial in collaboration with Washington University to treat patients with newly diagnosed glioblastoma multiforme and GT-30 is a clinical trial to treat patients with hepatocellular carcinoma.
The company intends to use the March 2023 funding to support its customized clinical trial.
Current Investors
Sante Ventures, Inovio Pharmaceuticals, Inc., Korea Investment Partners
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Molecular Science, Genetics & Gene Therapy, Oncology/Cancer Treatment, Pharmaceutical Research & Development
Website
www.geneostx.com
Verticals
HealthTech
Company Stage
Series A
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.